# Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Canonical URL: https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-commencement-of-halneuronr-chemotherapy-induced-neuropathic-pain-phase-2b-long-term-extension-study
Ticker: VIRI
Company: Virios Therapeutics
Source: Virios Therapeutics
Published: 2026-05-18 12:45 EST
Original Source URL: https://ir.dwtx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-20 12:30 EST — [Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026](https://biopharmsignal.com/news/VIRI/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-chemotherapy-in-dd9f404d) — Source: Virios Therapeutics
- 2026-06-30 12:45 EST — [Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-appoints-iain-dukes-venture-partner-at-orbimed-as-chair-of--8101d663) — Source: Virios Therapeutics
- 2026-05-18 12:45 EST — [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-commencement-of-halneuronr-chemotherapy-induced-neuropathic-pain-phase-2b-long-term-extension-study) — Source: Virios Therapeutics
- 2026-05-14 12:30 EST — [Dogwood Therapeutics Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-first-quarter-2026-financial-results) — Source: Virios Therapeutics
- 2026-05-07 12:30 EST — [Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026) — Source: Virios Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)